Fluorouracil vs Gemcitabine Chemotherapy Before and After Fluorouracil-Based Chemoradiation Following Resection of Pancreatic Adenocarcinoma
Top Cited Papers
Open Access
- 5 March 2008
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 299 (9) , 1019-1026
- https://doi.org/10.1001/jama.299.9.1019
Abstract
Despite potentially curative resection for pancreatic adenocarcinoma, patterns of failure analyses demonstrate a 50% to 85% component of local relapse associated with liver and intra-abdominal failure and a 5-year survival of less than 20%.1-5 The frequency and pattern of failure make the combination of adjuvant postoperative chemotherapy and radiation an important consideration. Phase 3 trials have demonstrated long-term survival of up to 20% of patients with resected adenocarcinoma of the pancreas treated with adjuvant fluorouracil-based chemoradiation (chemotherapy plus radiation).6-8 Although these trials have been small, their findings, combined with large institutional results,9,10 have supported the use of postoperative adjuvant chemoradiation with fluorouracil as a standard of care in the United States for more than 20 years.Keywords
This publication has 19 references indexed in Scilit:
- On Statistical Reanalysis, the EORTC Trial Is a Positive Trial for Adjuvant Chemoradiation in Pancreatic CancerAnnals of Surgery, 2006
- Postoperative Adjuvant Therapy: Past, Present, and Future Trial DevelopmentPublished by Springer Nature ,2006
- Combined modality adjuvant therapy for resected periampullary pancreatic and nonpancreatic adenocarcinoma: a review of studies and experience at The Johns Hopkins Hospital, 1991–2003Surgical Oncology Clinics of North America, 2004
- The randomization and stratification of patients to clinical trialsPublished by Elsevier ,2004
- Prediction of recurrence and survival by post-resection CA 19-9 values in patients with adenocarcinoma of the pancreasAnnals of Surgical Oncology, 1997
- Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.Journal of Clinical Oncology, 1997
- A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancerAnnals of Oncology, 1996
- Long-Term Survival After Resection for Ductal Adenocarcinoma of the Pancreas Is It Really Improving?Annals of Surgery, 1995
- Patterns of failure after curative resection of pancreatic carcinomaCancer, 1990
- Cancer of the pancreas: 50 years of surgeryCancer, 1987